Last activity: 06.03.2024
Categories: OptimizePhysicalLivingTechnologySmartBioTechBuildingAppDrugChemical
Ambrx Inc., is a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code. Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next-generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease.
Website visits
9.4K /mo.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $297M
Founded date: 2003

Investors 5

Funding Rounds 3


Mentions in press and media 21

06.03.2024Ambrx Shareholders Approve Acquisition by Johnson & John...-globenewsw...
09.01.2024Why Carta’s public battle might be a private markets nightma...To say the Carta news that broke over the weekend has caused a furor in the startup world is an
08.01.2024J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx...Big pharmaceutical companies splashed out big bucks in 2023 to acquire or license antibody drug conj...medcitynew...
20.06.2023This Startup Is Rewriting The Language Of Life To Make Smart...Pearl Bio co-founders: Michael Jewett, Amy Cayne Schwartz, and Farren Isaacs.Pearl
19.10.2022Biotech lay­offs con­tin­ue as Am­brx cuts staff and part of...It’s been no se­cret that this year has been rough for biotechs and em­ploy­ees, as com­pa­nies
21.06.2021Ad hoc announcement pursuant to Art. 53 Listing RulesHBM por...Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, comp...hbmhealthc...
07.01.2021Ambrx Appoints Gary Yeung as Chief Financial Officer and Chi...prnewswire...
24.11.2020Af­ter 5 qui­et years, a for­mer Scripps spin­out rais­es $2...The first time San Diego biotech Am­brx tried to go pub­lic in 2014, they failed and the com­pa­ny’
23.11.2020$200M investment to advance clinical programs for AmbrxInvestors in the $200 million round include Fidelity Management & Research Co., Cormorant Asset ...medcitynew...
23.11.2020Ambrx has raised a massive $200M round to advance work on it...-connect.or...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In